Human Pathology
Volume 41, Issue 1 , Pages 20-25 , January 2010

Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma

Received 3 June 2009 ,Revised 19 June 2009 ,Accepted 23 June 2009.

References 

  1. Travis W.D. Pathology of lung cancer. Clin Chest Med 2002;23:65-81,viii.
  2. Parkin M, Tyczynski JE, Boffetta P, Samet J, Shields P, Caporaso N. Lung cancer epidemiology and etiology. In:  Travis WD, et al. editor. World health organization classification of tumours. pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004;p. 12–15
  3. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88:1229–1233
  4. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non–small cell lung carcinomas. Hum Pathol. 2006;37:542–546
  5. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445–452
  6. Jerome Marson V, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology. 2004;45:125–134
  7. Johansson L. Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol. 2004;8:259–267
  8. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007;15:415–420
  9. Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann Oncol. 2007;18(Suppl 9):ix135–ix142
  10. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non–small cell lung cancer. Oncologist. 2007;12:713–718
  11. Herbst RS. Toxicities of antiangiogenic therapy in non–small-cell lung cancer. Clin Lung Cancer. 2006;8(Suppl 1):S23–S30
  12. Herbst RS, Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist. 2008;13:1166–1176
  13. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  14. Lam WK, Watkins DN. Lung cancer: future directions. Respirology. 2007;12:471–477
  15. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96:1105–1107
  16. Stang A, Pohlabeln H, Muller KM, Jahn I, Giersiepen K, Jockel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52:29–36
  17. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002;10:97–102
  18. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008;132:384–396
  19. Nicholson AG, McCormick CJ, Shimosato Y, Butcher DN, Sheppard MN. The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. Histopathology. 1995;27:57–60
  20. Hirano T, Auer G, Maeda M, et al. Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. Jpn J Cancer Res. 2000;91:1015–1021
  21. Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol. 2007;35:493–497
  22. Ueno T, Linder S, Na CL, Rice WR, Johansson J, Weaver TE. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem. 2004;279:16178–16184
  23. Schauer-Vukasinovic V, Bur D, Kling D, Gruninger F, Giller T, Human napsin A. Expression, immunochemical detection, and tissue localization. FEBS Lett. 1999;462:135–139
  24. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 2003;41:155–162

PII: S0046-8177(09)00235-4

doi: 10.1016/j.humpath.2009.06.014

Human Pathology
Volume 41, Issue 1 , Pages 20-25 , January 2010

Article Tools

* Image Usage & Resolution